Ebastin in the treatment of seasonal allergic rhinitis

Aim. To test the efficiency and tolerance of the second generation antihist amin drug ebastin (kestine) in patients with seasonal allergic rhinitis (SA R). Materials and methods. Kestin was given for 3 weeks in doses 10 and 20 mg/d ay to 226 patients with SAR running for 6.8 +/- 6.1 years. SAR symptoms rel ief subjective effects, side effects were studied. Results. The total index of rhinitis symptoms diminished from 11.6 to 1.2 s cores. Subjective response was registered in 82% of the patients, objective in 77%. Neither treatment aggravations nor serious side effects occurred. 2 patients had drowsiness, head aches, dizziness and discontinued Conclusion. Kestin is effective in SAR, had no serious side effects, is wel l tolerated.